Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IrelandIPO:
18 December 2012Website:
http://www.prothena.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:34:36 GMTDividend
Analysts recommendations
Institutional Ownership
PRTA Latest News
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Prothena (PRTA) lacks the necessary elements for a potential earnings beat in its upcoming report. Be ready with the important expectations.
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.
Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript
Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.
Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.
- 1(current)
What type of business is Prothena?
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
What sector is Prothena in?
Prothena is in the Healthcare sector
What industry is Prothena in?
Prothena is in the Biotechnology industry
What country is Prothena from?
Prothena is headquartered in Ireland
When did Prothena go public?
Prothena initial public offering (IPO) was on 18 December 2012
What is Prothena website?
https://www.prothena.com
Is Prothena in the S&P 500?
No, Prothena is not included in the S&P 500 index
Is Prothena in the NASDAQ 100?
No, Prothena is not included in the NASDAQ 100 index
Is Prothena in the Dow Jones?
No, Prothena is not included in the Dow Jones index
When does Prothena report earnings?
The next expected earnings date for Prothena is 02 August 2024